Evommune (EVMN) Share-based Compensation (2024 - 2026)
Evommune (EVMN) posted quarterly Share-based Compensation of $35.9 million for Q1 2026, up 3166.61% quarter-over-quarter from $1.1 million in Q4 2025.
Evommune (EVMN) Share-based Compensation (2024 - 2026) Analysis & Trends
Evommune (EVMN) has reported Share-based Compensation for 3 consecutive years, with $35.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation changed N/A year-over-year to $35.9 million; the TTM figure through Mar 2026 stood at $35.9 million (changed N/A YoY), while the FY2025 annual figure was $38.6 million, up 2141.58% from the prior year.
- Share-based Compensation grew to $35.9 million in Q1 2026 per EVMN's latest filing, from $1.1 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $35.9 million in Q1 2026 and bottomed at $401000.0 in Q3 2024.
- Historically, Share-based Compensation has averaged $8.7 million across 3 years, with a median of $1.1 million in 2025.
- On a YoY basis, Share-based Compensation climbed as much as 39.9% in 2025 and fell as far as 80.02% in 2025.
- Evommune's Share-based Compensation stood at $5.5 million in 2024, then plunged by 80.02% to $1.1 million in 2025, then surged by 3166.61% to $35.9 million in 2026.
- Business Quant data shows EVMN's Share-based Compensation at $35.9 million in Q1 2026, $1.1 million in Q4 2025, and $561000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Evommune | 531.53 Mn | 330.73 Mn | - | 4.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.60 Mn |
| Jun 30, 2026 | 4.60 Mn |
| Mar 31, 2026 | 35.90 Mn |
| Mar 31, 2026 | 35.90 Mn |
| Dec 31, 2025 | 1.10 Mn |
| Dec 31, 2025 | 1.10 Mn |
| Sep 30, 2025 | 561,000.00 |
| Sep 30, 2025 | 561,000.00 |
| Dec 31, 2024 | 5.50 Mn |
| Dec 31, 2024 | 5.50 Mn |
| Sep 30, 2024 | 401,000.00 |
| Sep 30, 2024 | 401,000.00 |